SlideShare a Scribd company logo
1 of 2
Download to read offline
Moving with the Times for
        Better Drug Development
                                           comes to finding ways to implement and     How can pharmaceutical          models
                                           transfer new ideas through the             better deliver to market?
                                           pharmaceutical process. Combining
                                           these two strengths increases              The increasing cost of developing
                                           productivity and decreases the time        compounds from idea to market is a
                                           needed for ideas to become tangible        major issue at the moment. Firm
                                           drugs in the market.                       decisions must be made on whether to
                                                                                      cease development of projects before
                                           What best practices provide true           they become very expensive. This way
                                           medical value?                             costs can be better controlled and the
                                                                                      outcome of clinical trials more positive.
                                           As the industry is proceeding into more
                                           of a collaboration mode, it is important
Interview with: Hasse Kromann,             that scientists be able to work across
Head of Section R&D Partnership            culture groups, industries and barriers.
Management,      Innovation  &
Research, LEO Pharma                       They should come out from behind their
                                           desks and really look at patient needs.
                                           This will spark innovation and provide
                                                                                       The industry
Drug discovery can create true
medical value when scientists work
                                           them with the inspiration needed to
                                           come up with bright ideas for new             should be
                                                                                         adaptable
across cultural groups and focus on        products that meet real-life needs.
patient needs and problems, says Hasse
Kromann, Head of Section R&D               How can open innovation platforms

                                                                                        and able to
Partnership Management, Innovation &       be designed to deliver compounds
Research, LEO Pharma. “This will spark     to the clinic in the future?
innovation and provide them with the
inspiration needed to come up with
bright ideas for new products,” he adds.
                                           The industry is currently experimenting
                                           with different platforms and ways of
                                           collaborating with biotech and academic
                                                                                           identify
A speaker at the marcus evans
Discovery Summit 2013, in Monte
                                           institutions to run fast exploratory
                                           clinical trials.                            which models
                                                                                         work best
Carlo, Monaco, 21 - 22 March, Kromann
discusses why proving concepts earlier     When this is achieved, the discovery
on in drug development will save           and clinical work will be bridged and

                                                                                         in specific
costs.                                     patients’ needs and problems can then
                                           take centre stage.
Why is close cooperation between
industry and academia so important
to drug discovery?
                                           Different platforms will suit different
                                           clinical objectives.                           projects
The pharmaceutical industry has the
ability to develop new drugs and
                                           The industry should be adaptable and
                                           able to identify which models work best        or issues
academia is very innovative when it        for specific projects or issues.
The Pharma Network – marcus                  About the Discovery Summit 2013
  evans Summits group delivers
  peer-to-peer          information     on     This unique forum will take place at Le Méridien Beach Plaza, Monte Carlo, Monaco,
  strategic     matters,    professional       21 - 22 March, 2013. Offering much more than any conference, exhibition or trade
  trends       and       breakthrough          show, this exclusive meeting will bring together esteemed industry thought leaders
  innovations.                                 and solution providers to a highly focused and interactive networking event. The
                                               Summit includes presentations and interactive forums on building bridges from pre-
                                               clinical to clinical studies and designing open innovation platforms.


                                               www.discovery-summit.com




  Please note that the Summit is a
  closed     business    event    and   the      Contact
  number      of   participants    strictly
  limited.                                       Maria Gregoriou, Journalist, marcus evans, Summits Division

                                                 Tel:     + 357 22 849 400
                                                 Email:   press@marcusevanscy.com

                                                 For more information please send an email to info@marcusevanscy.com


                                                 All rights reserved. The above content may be republished or reproduced. Kindly
                                                 inform us by sending an email to press@marcusevanscy.com




About marcus evans Summits

marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss
strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to
individually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings.


For more information, please visit: www.marcusevans.com



Upcoming Events

Evolution Summit (North America) - www.evolutionsummit.com


Evolution Summit (Europe) - www.evolution-summit.com




To view the web version of this interview, please click here: www.discovery-summit.com/HasseKromann

More Related Content

Similar to Moving with the Times for Better Drug Development: Interview with: Hasse Kromann, Head of Section R&D Partnership Management, Innovation & Research, LEO Pharma

Creativ-Ceutical Corporate Brochure
Creativ-Ceutical  Corporate BrochureCreativ-Ceutical  Corporate Brochure
Creativ-Ceutical Corporate Brochuremskarray
 
Driving Innovation In Bio Pharma W Plm
Driving Innovation In Bio Pharma W PlmDriving Innovation In Bio Pharma W Plm
Driving Innovation In Bio Pharma W PlmJenna Dudevoir
 
Collaboration across the pharma enterprise
Collaboration across the pharma enterpriseCollaboration across the pharma enterprise
Collaboration across the pharma enterpriseAmy Morgan
 
Single Use Bioreactors (2012)
Single Use Bioreactors (2012)Single Use Bioreactors (2012)
Single Use Bioreactors (2012)shad121
 
Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Pranita Nangia
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)shad121
 
Moorhouse_PharmaConsumerBusiness_NPD_whitepaper
Moorhouse_PharmaConsumerBusiness_NPD_whitepaperMoorhouse_PharmaConsumerBusiness_NPD_whitepaper
Moorhouse_PharmaConsumerBusiness_NPD_whitepaperJabar Kazmi
 
Pharma IQ - Clinical Series 2011
Pharma IQ - Clinical Series 2011Pharma IQ - Clinical Series 2011
Pharma IQ - Clinical Series 2011Pharma IQ
 
'Setting New Standards...one small company brings industry giants together'
'Setting New Standards...one small company brings industry giants together''Setting New Standards...one small company brings industry giants together'
'Setting New Standards...one small company brings industry giants together'The Avoca Group
 
PharmaVoice 2013 - Market Research Best Practices
PharmaVoice 2013 - Market Research Best PracticesPharmaVoice 2013 - Market Research Best Practices
PharmaVoice 2013 - Market Research Best PracticesDev Das
 
3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) PpPiyush Patel
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.Merck Life Sciences
 
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...Engineers Australia
 
Oi in sme's remarks
Oi in sme's remarksOi in sme's remarks
Oi in sme's remarkspsaradis
 

Similar to Moving with the Times for Better Drug Development: Interview with: Hasse Kromann, Head of Section R&D Partnership Management, Innovation & Research, LEO Pharma (20)

Creativ-Ceutical Corporate Brochure
Creativ-Ceutical  Corporate BrochureCreativ-Ceutical  Corporate Brochure
Creativ-Ceutical Corporate Brochure
 
Driving Innovation In Bio Pharma W Plm
Driving Innovation In Bio Pharma W PlmDriving Innovation In Bio Pharma W Plm
Driving Innovation In Bio Pharma W Plm
 
PMC7
PMC7PMC7
PMC7
 
Collaboration across the pharma enterprise
Collaboration across the pharma enterpriseCollaboration across the pharma enterprise
Collaboration across the pharma enterprise
 
Mbis Presentation University
Mbis Presentation  UniversityMbis Presentation  University
Mbis Presentation University
 
Single Use Bioreactors (2012)
Single Use Bioreactors (2012)Single Use Bioreactors (2012)
Single Use Bioreactors (2012)
 
Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)Aesthetics and anti ageing (2011)
Aesthetics and anti ageing (2011)
 
11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)11th Annual Biosimilars Uk (2012)
11th Annual Biosimilars Uk (2012)
 
Innovation At 3M
Innovation At 3MInnovation At 3M
Innovation At 3M
 
Med_Man_H1_Del
Med_Man_H1_DelMed_Man_H1_Del
Med_Man_H1_Del
 
Moorhouse_PharmaConsumerBusiness_NPD_whitepaper
Moorhouse_PharmaConsumerBusiness_NPD_whitepaperMoorhouse_PharmaConsumerBusiness_NPD_whitepaper
Moorhouse_PharmaConsumerBusiness_NPD_whitepaper
 
Pharma IQ - Clinical Series 2011
Pharma IQ - Clinical Series 2011Pharma IQ - Clinical Series 2011
Pharma IQ - Clinical Series 2011
 
'Setting New Standards...one small company brings industry giants together'
'Setting New Standards...one small company brings industry giants together''Setting New Standards...one small company brings industry giants together'
'Setting New Standards...one small company brings industry giants together'
 
Innovation - The role of standards
Innovation - The role of standardsInnovation - The role of standards
Innovation - The role of standards
 
PharmaVoice 2013 - Market Research Best Practices
PharmaVoice 2013 - Market Research Best PracticesPharmaVoice 2013 - Market Research Best Practices
PharmaVoice 2013 - Market Research Best Practices
 
3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp3rd Annual Vaccine Manufacturing (2011) Pp
3rd Annual Vaccine Manufacturing (2011) Pp
 
Industry Trends in Innovation
Industry Trends in InnovationIndustry Trends in Innovation
Industry Trends in Innovation
 
The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.The Future of Bioprocessing – What you need to know.
The Future of Bioprocessing – What you need to know.
 
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...
ICWES15 - Medical Devices - Partnering for Success. Presented by Prof Karen R...
 
Oi in sme's remarks
Oi in sme's remarksOi in sme's remarks
Oi in sme's remarks
 

More from Life Sciences Network marcus evans

The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...Life Sciences Network marcus evans
 
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisOptimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisLife Sciences Network marcus evans
 
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKLife Sciences Network marcus evans
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Life Sciences Network marcus evans
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Life Sciences Network marcus evans
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedLife Sciences Network marcus evans
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessLife Sciences Network marcus evans
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Life Sciences Network marcus evans
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Life Sciences Network marcus evans
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...Life Sciences Network marcus evans
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Life Sciences Network marcus evans
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Life Sciences Network marcus evans
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Life Sciences Network marcus evans
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Life Sciences Network marcus evans
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Life Sciences Network marcus evans
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Life Sciences Network marcus evans
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Life Sciences Network marcus evans
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Life Sciences Network marcus evans
 

More from Life Sciences Network marcus evans (20)

The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...The Power of Digital Measures in Clinical Trials  - Erwin De beuckelaer, Jans...
The Power of Digital Measures in Clinical Trials - Erwin De beuckelaer, Jans...
 
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClisOptimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
Optimizing Clinical Trial Operations - Alexander Fetkovsky, SanaClis
 
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSKHow Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
How Sponsors and Vendors Can Form a True Partnership-Kristine Koontz, GSK
 
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...Technological Crossroads: Navigating the Intersection between Recruitment, Re...
Technological Crossroads: Navigating the Intersection between Recruitment, Re...
 
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
Beyond the Hype: Practical Approaches for Implementing Machine Learning and A...
 
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) RedefinedKeeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
Keeping up with ICH E6(R2): Risk-Based Monitoring (RBM) Redefined
 
Turning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for SuccessTurning Sponsor/CRO Relationships into Partnerships for Success
Turning Sponsor/CRO Relationships into Partnerships for Success
 
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
Evolving Risk-Based Monitoring to Improve Clinical Studies-Dunya Botetzayas, ...
 
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
Discovering Key Regulatory Reforms to Enable Accelerated Drug Development and...
 
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
The Patient’s Perspective: Finding a Cure to Rare Genetic Diseases - Dr Nicol...
 
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
Targeting Ras and MDS: Rigosertib Taking Aim at Important Targets-Steven Fruc...
 
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...Individualizing Patient Care through Precision Medicine: Shaping the Industry...
Individualizing Patient Care through Precision Medicine: Shaping the Industry...
 
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
Collaboration between Industry and Academia – An Opportunity to Drive Efficie...
 
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...Considering the End before the Beginning: Choosing the Correct Endpoints - An...
Considering the End before the Beginning: Choosing the Correct Endpoints - An...
 
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
Pushing the Innovation Envelope: Strategies for Boosting Productivity and ROI...
 
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
Biomarkers to Diagnostics – The Essential Tool Box for Drug Development - Joh...
 
Business Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENABusiness Development Activities Interview - Clinart MENA
Business Development Activities Interview - Clinart MENA
 
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
Strategies for Maximizing Pediatric Studies: Orphan Indications - Deborah Lee...
 
Where marcus evans fits in our business development mix
Where marcus evans fits in our business development mixWhere marcus evans fits in our business development mix
Where marcus evans fits in our business development mix
 
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
Forming Powerful Partnerships to Drill Down into the Areas of Expertise of Ea...
 

Moving with the Times for Better Drug Development: Interview with: Hasse Kromann, Head of Section R&D Partnership Management, Innovation & Research, LEO Pharma

  • 1. Moving with the Times for Better Drug Development comes to finding ways to implement and How can pharmaceutical models transfer new ideas through the better deliver to market? pharmaceutical process. Combining these two strengths increases The increasing cost of developing productivity and decreases the time compounds from idea to market is a needed for ideas to become tangible major issue at the moment. Firm drugs in the market. decisions must be made on whether to cease development of projects before What best practices provide true they become very expensive. This way medical value? costs can be better controlled and the outcome of clinical trials more positive. As the industry is proceeding into more of a collaboration mode, it is important Interview with: Hasse Kromann, that scientists be able to work across Head of Section R&D Partnership culture groups, industries and barriers. Management, Innovation & Research, LEO Pharma They should come out from behind their desks and really look at patient needs. This will spark innovation and provide The industry Drug discovery can create true medical value when scientists work them with the inspiration needed to come up with bright ideas for new should be adaptable across cultural groups and focus on products that meet real-life needs. patient needs and problems, says Hasse Kromann, Head of Section R&D How can open innovation platforms and able to Partnership Management, Innovation & be designed to deliver compounds Research, LEO Pharma. “This will spark to the clinic in the future? innovation and provide them with the inspiration needed to come up with bright ideas for new products,” he adds. The industry is currently experimenting with different platforms and ways of collaborating with biotech and academic identify A speaker at the marcus evans Discovery Summit 2013, in Monte institutions to run fast exploratory clinical trials. which models work best Carlo, Monaco, 21 - 22 March, Kromann discusses why proving concepts earlier When this is achieved, the discovery on in drug development will save and clinical work will be bridged and in specific costs. patients’ needs and problems can then take centre stage. Why is close cooperation between industry and academia so important to drug discovery? Different platforms will suit different clinical objectives. projects The pharmaceutical industry has the ability to develop new drugs and The industry should be adaptable and able to identify which models work best or issues academia is very innovative when it for specific projects or issues.
  • 2. The Pharma Network – marcus About the Discovery Summit 2013 evans Summits group delivers peer-to-peer information on This unique forum will take place at Le Méridien Beach Plaza, Monte Carlo, Monaco, strategic matters, professional 21 - 22 March, 2013. Offering much more than any conference, exhibition or trade trends and breakthrough show, this exclusive meeting will bring together esteemed industry thought leaders innovations. and solution providers to a highly focused and interactive networking event. The Summit includes presentations and interactive forums on building bridges from pre- clinical to clinical studies and designing open innovation platforms. www.discovery-summit.com Please note that the Summit is a closed business event and the Contact number of participants strictly limited. Maria Gregoriou, Journalist, marcus evans, Summits Division Tel: + 357 22 849 400 Email: press@marcusevanscy.com For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.com About marcus evans Summits marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-to-one business meetings. For more information, please visit: www.marcusevans.com Upcoming Events Evolution Summit (North America) - www.evolutionsummit.com Evolution Summit (Europe) - www.evolution-summit.com To view the web version of this interview, please click here: www.discovery-summit.com/HasseKromann